AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia
NCT ID: NCT00180128
Last Updated: 2011-07-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
80 participants
INTERVENTIONAL
2000-01-31
2012-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA)
NCT00465933
AIDA 2000 Guidelines
NCT01064570
Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia
NCT02688140
Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia
NCT01226303
Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005)
NCT00408278
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
PREVENTION
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
all-trans retinoid acid
idarubicin
mitoxantrone
daunorubicin
cytarabine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* no contraindication for chemotherapy
* written informed consent
Exclusion Criteria
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Technische Universität Dresden
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dresden University of Technology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gerhard Ehninger, MD
Role: PRINCIPAL_INVESTIGATOR
Department of Medicine I, University Hospital Carl Gustav Carus Dresden
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Medicine I, University Hospital Carl Gustav Carus
Dresden, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MK1-192
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.